id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-3616-0003,FDA,FDA-2017-E-3616,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-08-03T04:00:00Z,2017,8,2017-08-03T04:00:00Z,,2017-08-03T14:42:13Z,,0,0,090000648299ad22
FDA-2017-E-3616-0002,FDA,FDA-2017-E-3616,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2017-06-09T04:00:00Z,2017,6,2017-06-09T04:00:00Z,,2017-06-09T13:39:21Z,,0,0,09000064826b5bbc
FDA-2017-E-3616-0001,FDA,FDA-2017-E-3616,"Patent Extension Application fromSquire Patton Boggs (US) LLP (on behalf of ABBOTT CARDIOVASCULAR SYSTEMS INC. (""ABBOTT""))",Other,Application,2017-06-09T04:00:00Z,2017,6,2017-06-09T04:00:00Z,,2017-06-09T13:36:47Z,,0,0,09000064826b5af1